Patient-Reported Tolerability of Adjuvant Ipilimumab vs High-Dose Interferon for Resected High-Risk Stage III–IV Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609
Qual Life Res 2022 Aug 27;[EPub Ahead of Print], LE McLouth, Y Zheng, S Smith, FS Hodi, UN Rao, GI Cohen, TT Amatruda, SR Dakhil, BD Curti, I Nakhoul, SR Chandana, CL Bane, DE Marinier, SJ Lee, VK Sondak, JM Kirkwood, AA Tarhini, LI WagnerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.